Back to Search
Start Over
Intravesical bacillus Calmette-Guerin for patients with high-risk superficial bladder cancer.
- Source :
-
Urology [Urology] 1991 Feb; Vol. 37 (2), pp. 180-4. - Publication Year :
- 1991
-
Abstract
- Intravesical bacillus Calmette-Guérin (BCG) was employed in the treatment of 55 patients with aggressive superficial transitional cell carcinoma of the bladder (cTa, cT1, cTis). All of the patients had a previous history of recurrent superficial disease, and 41 (75%) were treatment failures following other intravesical therapy. Thirty-six (66%) patients responded to treatment, and 19 (34%) were treatment failures. Twenty-seven (66%) of 41 patients with cTa-cT1 tumors and 9 (64%) of 14 patients with cTis responded, with a mean follow-up period of 30.5 months. Disease progression was noted in 8 (15%) of the patients and muscle invasive disease in 6. Patients with a history of three or more previous events of tumor recurrence, positive urinary cytology, and multicentric disease, all fared worse than patients without these characteristics (p less than 0.05). BCG is an effective agent in controlling superficial transitional cell carcinoma of the bladder, even in a high-risk group of patients who failed previous intravesical therapy. BCG should be employed in this group of patients prior to radical surgery.
- Subjects :
- Administration, Intravesical
Adult
Aged
Aged, 80 and over
BCG Vaccine adverse effects
Carcinoma, Transitional Cell pathology
Female
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
Urinary Bladder Neoplasms pathology
BCG Vaccine administration & dosage
Carcinoma, Transitional Cell therapy
Urinary Bladder Neoplasms therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0090-4295
- Volume :
- 37
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Urology
- Publication Type :
- Academic Journal
- Accession number :
- 1992591
- Full Text :
- https://doi.org/10.1016/0090-4295(91)80221-r